Journal article
Exceptional responses with sequential metronomic temozolomide after pembrolizumab failure in patients with metastatic melanoma
Melanoma research, Vol.29(6), pp.643-647
12/2019
DOI: 10.1097/CMR.0000000000000592
PMID: 30829928
Abstract
Pembrolizumab is an effective therapy in patients with metastatic melanoma. However, not all patients derive benefit. It is postulated that an increase in regulatory T cells in melanoma patients can impair the response to immunotherapies. Continuous low dose temozolomide has shown to cause immunomodulatory effects resulting in CD4+ lymphopenia due to which T-reg population can also decrease significantly. Herein we present a case series of 3 patients with metastatic melanoma who after progression on pembrolizumab showed a radiological response after just 1 cycle of metronomic temozolomide (75 mg/m
2
daily for 6 weeks on 8-week cycle). This suggests that temozolomide may be a useful alternative for patients with metastatic melanoma after disease progression on pembrolizumab. Further studies with biomarkers are warranted to elucidate which patients will derive benefit from this strategy.
Details
- Title: Subtitle
- Exceptional responses with sequential metronomic temozolomide after pembrolizumab failure in patients with metastatic melanoma
- Creators
- Umang Swami - University of Iowa Hospitals and ClinicsVarun Monga - University of Iowa Hospitals and ClinicsMichele Freesmeier - University of Iowa Hospitals and ClinicsWeizhou Zhang - University of Iowa Hospitals and ClinicsAaron D Bossler - University of Iowa Hospitals and ClinicsYousef Zakharia - University of Iowa Hospitals and ClinicsMohammed Milhem - University of Iowa Hospitals and Clinics
- Resource Type
- Journal article
- Publication Details
- Melanoma research, Vol.29(6), pp.643-647
- DOI
- 10.1097/CMR.0000000000000592
- PMID
- 30829928
- NLM abbreviation
- Melanoma Res
- ISSN
- 0960-8931
- eISSN
- 1473-5636
- Language
- English
- Date published
- 12/2019
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Pathology; Radiation Oncology; Internal Medicine
- Record Identifier
- 9984185278702771
Metrics
15 Record Views